Stem cell research opens up prospect of profitable exports
RNL Bio, a South Korean biotech company, is venturing into the world of treating human diseases through stem cell therapies, raising the prospects of a new, highly profitable export industry.
The company, famous for the commercial cloning of dogs, is developing therapies using adult stem cells to treat degenerative diseases
Publication Date:
21/05/2009